Enrique A.  Conterno net worth and biography

Enrique Conterno Biography and Net Worth

Enrique Conterno Chief Executive Officer at FibroGen, Inc. Attended at Duke University - The Fuqua School of Business.

What is Enrique A. Conterno's net worth?

The estimated net worth of Enrique A. Conterno is at least $274.37 million as of July 7th, 2023. Mr. Conterno owns 374,722 shares of Eli Lilly and Company stock worth more than $274,371,448 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Conterno may own. Learn More about Enrique A. Conterno's net worth.

How do I contact Enrique A. Conterno?

The corporate mailing address for Mr. Conterno and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Enrique A. Conterno's contact information.

Has Enrique A. Conterno been buying or selling shares of Eli Lilly and Company?

Enrique A. Conterno has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, Enrique A. Conterno sold 25,000 shares of the business's stock in a transaction on Friday, February 15th. The shares were sold at an average price of $121.00, for a transaction totalling $3,025,000.00. Learn More on Enrique A. Conterno's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 31 times. They sold a total of 2,074,936 shares worth more than $21,628,352,978.48. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 1/31/2024.

Enrique A. Conterno Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2019Sell25,000$121.00$3,025,000.00View SEC Filing Icon  
5/31/2018Sell25,000$85.00$2,125,000.00View SEC Filing Icon  
5/4/2017Sell25,000$82.76$2,069,000.00114,217View SEC Filing Icon  
12/9/2015Sell25,000$83.88$2,097,000.0088,131View SEC Filing Icon  
11/3/2014Sell5,000$66.03$330,150.00View SEC Filing Icon  
10/1/2014Sell5,000$64.86$324,300.00View SEC Filing Icon  
9/2/2014Sell5,000$63.60$318,000.00View SEC Filing Icon  
7/25/2014Sell10,000$63.79$637,900.00View SEC Filing Icon  
7/15/2013Sell5,000$51.43$257,150.00View SEC Filing Icon  
6/17/2013Sell5,000$52.45$262,250.00View SEC Filing Icon  
5/15/2013Sell5,000$56.15$280,750.00View SEC Filing Icon  
See Full Table

Enrique A. Conterno Buying and Selling Activity at Eli Lilly and Company

This chart shows Enrique A Conterno's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $732.20
Low: $728.79
High: $752.64

50 Day Range

MA: $763.40
Low: $726.31
High: $792.28

2 Week Range

Now: $732.20
Low: $370.68
High: $800.78

Volume

2,052,626 shs

Average Volume

2,303,675 shs

Market Capitalization

$695.71 billion

P/E Ratio

126.24

Dividend Yield

0.70%

Beta

0.34